Back to Biomarkers List
Associated Genetic Biomarkers
GEN1 is altered in 1.95% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, glioblastoma, and melanoma having the greatest prevalence of alterations .
The most common alterations in GEN1 are GEN1 Mutation (1.66%), GEN1 Nonsense (0.13%), GEN1 Amplification (0.06%), GEN1 T765S (0.06%), and GEN1 Deletion (0.05%) .
GEN1 status serves as an inclusion eligibility criteria in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials that contain GEN1 status as an inclusion criterion, 4 are phase 2 (4 open).
Trials with GEN1 status in the inclusion eligibility criteria most commonly target prostate adenocarcinoma, adenocarcinoma of the gastroesophageal junction, esophageal adenocarcinoma, gastric adenocarcinoma, and prostate carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are GEN1 Loss and GEN1 Mutation .
Niraparib, durvalumab, olaparib, and rucaparib are the most frequent therapies in trials with GEN1 as an inclusion criteria .
Significance of GEN1 in Diseases
Prostate Adenocarcinoma +
GEN1 is altered in 1.57% of prostate adenocarcinoma patients .
GEN1 is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain GEN1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) .
Gastric Adenocarcinoma +
Adenocarcinoma Of The Gastroesophageal Junction +
GEN1 is altered in 2.7% of adenocarcinoma of the gastroesophageal junction patients .
GEN1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) .
Prostate Carcinoma +
Esophageal Adenocarcinoma +
GEN1 is altered in 1.21% of esophageal adenocarcinoma patients .
GEN1 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.